HCA Healthcare, Inc.
469.03USD
+1.7200 (+0.37%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HCA.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $6.63▼ | $7 | 0 | 3 |
| Next quarter | $8.06▼ | $8.11 | 2 | 1 |
| Current year | $29.49▼ | $29.92 | 0 | 1 |
| Next year | $31.99▼ | $32.74 | 0 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $7.5 | $7.59 | +0.09 (+1.2%) |
| 2026-03-31 | $7.13 | $7.15 | +0.02 (+0.3%) |
| 2025-12-31 | $7.48 | $8.01 | +0.53 (+7.1%) |
| 2025-09-30 | $5.73 | $6.96 | +1.23 (+21.6%) |
428 ratings from 43 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $431 $460 | Oct 12, 2026 |
| RBC Capital | Maintained | Outperform | $435 $496 | Oct 7, 2026 |
| BMO Capital | Initiated | Outperform | $495 | Sep 23, 2026 |
| Leerink Partners | Maintained | Outperform | $492 | Sep 18, 2026 |
| RBC Capital | Reiterated | Outperform | $435 | Sep 8, 2026 |
| JP Morgan | Maintained | Neutral | $490 $425 | Aug 20, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $369 $381 | Aug 3, 2026 |
| Goldman Sachs | Maintained | Buy | $558 $485 | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $525 $475 | Jul 28, 2026 |
| UBS | Maintained | Buy | $635 $579 | Jul 27, 2026 |
| Morgan Stanley | Maintained | Underweight | $425 $380 | Jul 27, 2026 |
| RBC Capital | Reiterated | Outperform | $435 | Jul 27, 2026 |
| Truist Securities | Maintained | Buy | $535 $495 | Jul 27, 2026 |
| Oppenheimer | Maintained | Outperform | $520 $485 | Jul 27, 2026 |
| Keybanc | Maintained | Overweight | $475 $435 | Jul 27, 2026 |
| Baird | Maintained | Neutral | $396 $393 | Jul 27, 2026 |
| Barclays | Maintained | Equal-Weight | $402 $387 | Jul 27, 2026 |
| Barclays | Maintained | Equal-Weight | $427 $402 | Jul 16, 2026 |
| RBC Capital | Maintained | Outperform | $534 $435 | Jul 15, 2026 |
| Keybanc | Maintained | Overweight | $510 $475 | Jul 14, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $436 $428 | Jul 13, 2026 |
| Barclays | Downgraded from Overweight | Equal-Weight | $496 $427 | Jul 8, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $588 $525 | Jul 7, 2026 |
| TD Cowen | Maintained | Buy | $500 $431 | Jun 22, 2026 |
| Bernstein | Maintained | Market Perform | $503 $413 | Jun 4, 2026 |
68 filings from 21 insiders · 0 buy / 0 sell over 6m
Officers and directors of HCA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MARKS MIKE AChief Financial Officer | Gift | 3.3k | — | — | May 7, 2026 |
| SMITH ANDREA BDirector | Grant | 509 | — | — | Apr 28, 2026 |
| MICHELSON MICHAEL WDirector | Grant | 925 | — | — | Apr 28, 2026 |
| CHIDSEY JOHN WDirector | Grant | 809 | — | — | Apr 28, 2026 |
| DEPARLE NANCY-ANN M. J.D.Director | Grant | 509 | — | — | Apr 28, 2026 |
| RILEY WAYNE JOSEPHDirector | Grant | 509 | — | — | Apr 28, 2026 |
| FRIST THOMAS F IIIDirector and Beneficial Owner of more than 10% of a Class of Security | Grant | 1.0k | — | — | Apr 28, 2026 |
| JOHNSTON HUGH F.Director | Grant | 809 | — | — | Apr 28, 2026 |
| FRIST WILLIAM R.Director and Beneficial Owner of more than 10% of a Class of Security | Grant | 809 | — | — | Apr 28, 2026 |
| MCALEVEY MICHAEL R.Officer | Sell | 1.7k | $533.37 | $904k | Feb 18, 2026 |
| MCALEVEY MICHAEL R.Officer | Exercise | 5.0k | $236.61 | $1.18M | Feb 13, 2026 |
| WYATT CHRISTOPHER FOfficer | Sell | 4.0k | $505.00 | $2.02M | Feb 11, 2026 |
| BERRES JENNIFEROfficer | Sell | 8.0k | $503.00 | $4.13M | Feb 11, 2026 |
| BERRES JENNIFEROfficer | Grant | 7.1k | — | — | Feb 10, 2026 |
| MCALEVEY MICHAEL R.Officer | Grant | 8.4k | — | — | Feb 10, 2026 |
| MARKS MIKE AChief Financial Officer | Grant | 5.0k | — | — | Feb 10, 2026 |
| ROSSITTO ERICAOfficer | Grant | 1.7k | — | — | Feb 10, 2026 |
| CUFFE MICHAEL SOfficer | Grant | 9.6k | — | — | Feb 10, 2026 |
| WYATT CHRISTOPHER FOfficer | Grant | 3.4k | — | — | Feb 10, 2026 |
| HAZEN SAMUEL NChief Executive Officer | Grant | 54.9k | — | — | Feb 10, 2026 |
No analyst notes on HCA yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 14 | 9 | 1 | 1 | Hold2.50 |
| 1 mo ago | 1 | 14 | 10 | 1 | 0 | Buy2.42 |
| 2 mo ago | 1 | 13 | 10 | 1 | 0 | Buy2.44 |
| 3 mo ago | 1 | 13 | 10 | 1 | 0 | Buy2.44 |
Members whose judged calls on HCA have played out most reliably.
No settled calls on HCA yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice